Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RS Group maintains outlook despite revenue decline

(Sharecast News) - RS Group said in an update on Thursday that its full-year outlook remained unchanged, despite reporting a 2% decline in like-for-like revenue for the first quarter ended 30 June. The FTSE 250 industrial solutions provider, which was holding its annual general meeting, cited softer purchasing manager indices (PMIs) in EMEA as a drag on performance, although trading in the Americas and Asia Pacific remained more resilient.

Adjusting for temporary impacts related to operational upgrades, the company said trading was broadly flat.

During the quarter, RS Group said it advanced key elements of its strategic action plan, including a digital platform upgrade in the Americas and the consolidation of a Distrelec distribution centre in EMEA.

The company said it was continuing to invest in strengthening its proposition, improving operational efficiency, and growing market share, while maintaining agility in pricing and cost control.

"We are confident that this will generate sustainable value and stronger returns as markets recover, in line with our medium-term financial targets," the group said.

At 0907 BST, shares in RS Group were down 1.12% at 571.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.